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Abstract
Background: Prospective population-based neuropathological studies have a special place in
dementia research which is under emphasised.
Methods: A systematic review of the methods of population-based neuropathological studies of
dementia was carried out. These studies were assessed in relation to their representativeness of
underlying populations and the clinical, neuropsychological and neuropathological approaches
adopted.
Results: Six studies were found to be true population-based neuropathological studies of dementia
in the older people: the Hisayama study (Japan); Vantaa 85+ study (Finland); CC75C study
(Cambridge, UK); CFAS (multicentre, UK); Cache County study (Utah, USA); HAAS (Hawaï, USA).
These differ in the core characteristics of their populations. The studies used standardised
neuropathological methods which facilitate analyses on: clinicopathological associations and
confirmation of diagnosis, assessing the validity of hierarchical models of neuropathological lesion
burden; investigating the associations between neuropathological burden and risk factors including
genetic factors. Examples of findings are given although there is too little overlap in the areas
investigated amongst these studies to form the basis of a systematic review of the results.
Conclusion: Clinicopathological studies based on true population samples can provide unique
insights in dementia. Individually they are limited in power and scope; together they represent a
powerful source to translate findings from laboratory to populations.
Background
Within the next two decades unprecedented numbers of
people will be entering the age range at which incidence
of dementing diseases is highest. The EURODEM Preva-
lence Research Group estimates that 6% of people over
the age of 65 will suffer from dementia, with 30% in the
over 80s [1]. The economic cost of Alzheimer's Disease
(AD) is already higher than that of heart disease and can-
cer combined [2]. The high dependency associated with
dementia, with its costs and consequences for society,
gives research into the aetiology and pathogenesis of late
life dementia major priority.
Dementia research based on human brain tissues ranges
from observation of the pathology of selected individuals
to investigate the molecular mechanisms of dementia to
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population-based studies to understand who, where and
why people develop dementia [3-7]. A substantial contri-
bution to our understanding of the pathology, neuro-
chemistry, molecular pathology and genetics of different
types of dementias has arisen from the observation on the
brains of individuals who have been demented during
life. These studies have been key to recent advances in
understanding dementing disorders. All clinicopathologi-
cal studies can investigate the performance of in life diag-
nostic methods to after life brain appearances but very few
studies have combined this detailed molecular approach
to understanding the neuropathological findings in a
population context. Most pathological studies in the eld-
erly have drawn on cases from nursing homes, acute med-
ical units, hospital patients, volunteer cohorts or ordinary
post-mortem series [8,9]. However, it is known that selec-
tion bias resulting from referral of patients from primary
to secondary and on to tertiary care centres can affect pro-
foundly the results of clinical or epidemiological studies
[10]. This is because referral is influenced by more than
the severity of the disorder itself and has much to do with
the way that communities contain and deal with aberrant
behaviour [11]. Referral may differ according to burden of
symptoms, access to care, popularity of disorders special-
isation and institutions (e.g. the 'Berkson paradox' [10]).
Furthermore specialised patient research groups derived
from referrals typically use stringent selection criteria so
that patients are usually selected to have fewer co-morbid
conditions. Potential referral biases have rarely been
investigated systematically in studies of pathology in
dementia cohorts. Differences in sociodemographic char-
acteristics of three groups of patients with AD from differ-
ent sources in the US have been reported as significant.
The patients being compared were population-based
patients, patients referred from a near distance (primary
or secondary care), and patients referred from a far dis-
tance (tertiary care) [12]. Such biases in sociodemo-
graphic variables have important implications for
research because some of these variables have been impli-
cated as risk factors for AD. One of these is age at onset of
symptoms, which can be a marker of the severity, the
genetic nature, and the clinical course of AD. The discrep-
ancy between the general population and samples of
research respondents in cohort studies based on medical
Pathways through which individuals may be filtered before becoming potential research respondents Figure 1
Pathways through which individuals may be filtered before becoming potential research respondents. Note: In systems such as 
in the UK, referral from secondary and tertiary services is almost always through primary care. This is not the case in all health 
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access is shown in Figure 1. It is usually not possible to
determine whether the findings on a selected research
group can be generalised to the whole population, and it
is likely that mostly they are not. This also applies to all
volunteer cohorts. For example, the Nun study respond-
ents are members of the School Sisters of Notre Dame reli-
gious congregation. These participants, who have chosen
to be a member of a group rather than being born into it,
have been in a controlled geographical and social envi-
ronment with little heterogeneity of exposure of potential
risk factors since puberty. This has some advantages in
investigating specific hypotheses but it is difficult to esti-
mate the effects of this selection on the generalisability of
any findings to the population as a whole. This means
claims regarding the possible effect size of risk factors on
the importance of any particular pathology are often
based mostly on potentially biased findings in highly
selected populations. The proportions of various types of
dementing disorders could be artificially skewed by the
participation of a non-representative sample of the total
demented population. For extrapolation of results to the
population to be valid, research must be conducted on a
true population sample, or on groups with well character-
ised biases. Working with truly population-based studies
is the best way to minimize misinterpretation and bias.
Beyond the pathological confirmation of diagnosis, and
the inherent generalisability of the data, working with
population-based neuropathological studies allows a
range of further investigations (along with cohort stud-
ies). These include identification of brain lesions that
relate best to cognitive decline, and the examination of
links between pathologies and potential risk factors. This
approach highlights the significance of brain lesions as
substrates for the decline noted in normal ageing in com-
parison to the demented [11]. Because population
cohorts naturally represent spectra of disease, it is possible
to test hypothetical semi-quantitative thresholds defina-
ble in terms of a staging system [13,14] that might dis-
criminate clinical dementia and illuminate critical steps in
the neurobiological progression of cognitive decline
through states such as Mild Cognitive Impairment. Thus
identifying neuropathological markers relevant to cogni-
tive function both helps in the diagnostic process and the
understanding of the molecular and clinical aetiology of
dementias and ultimately results in the development of
better treatments.
Prospective population-based neuropathological studies
allow findings of clinicopathological cohort studies to
have a special place in dementia research which is under
emphasised. This paper reports a systematic literature
review of the methods of on-going population-based neu-
ropathological studies of old age dementia, assesses the
representativeness of the study populations included in
each, and reviews their neuropathological methods.
Examples of findings from population-based studies will
be discussed to illustrate the range of areas investigated.
Methods
Literature data sources and search strategy
A systematic review is the application of strategies that
limit bias in the assembly, critical appraisal and synthesis
of all relevant studies on a specific topic [115]. Systematic
reviews focus on peer-reviewed publications about a spe-
cific health problem and use vigorous, standardised meth-
ods for selecting and assessing each article. A search was
performed in July 2004 using the entire Medline,
PubMed, Embase and Web of Science databases without
using any language restrictions. The following key words
were used to perform multiple searches: dementia, neu-
ropathol*, autopsy, population, community. The search
was not straightforward in that it was difficult to pinpoint
an adequate MeSH word in PubMed or use the explode
options in other databases to select for truly population-
based studies. To solve this problem keywords cited with
relevant articles already retrieved were scoped and used in
the search strategy. However, this approach did not yield
additional target publications. A preliminary list of 4,048
papers were traced and a first selection was made based on
their title and abstracts. These 4,048 papers do not repre-
sent 4,000+ different cohorts but all the publications from
a smaller number of cohorts. Key authors were contacted
and key studies were also followed in order to trace
descriptions of original study designs. The search was dis-
continued when no new studies were being found. Data
within articles directly reporting population-based neu-
ropathological studies of dementia in the elderly were
extracted using a data collection proforma designed spe-
cifically for this review.
Study selection
The aim of the literature search was to gather information
on all studies that are population-based neuropathologi-
cal studies of dementia. These are studies where a general
population defined by geographical boundaries is the
sampling frame [115]. Respondents must be recruited
from all sub-groups of the population, whatever the social
background, residential status (community or institu-
tional) or health status. Studies were included if they did
not have selection criteria for the respondents related to
'caseness' or potential 'caseness', and if they sought post-
mortem examination of the brains of respondents across
all cognitive states.
Results
List of studies and study populations meeting inclusion 
criteria
Six studies were found to be true population-based neu-
ropathological studies on old age dementia. They areB
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Table 1: Key information from the community-based neuropathological studies of old age dementia
Study Hisayama study CC75C Vantaa 85+ CFAS HAAS Cache County study
Nottingham
Gwynedd
Newcastle
Cambridgeshire
Oxford
Liverpool*
Start date 1985 (for dementia 
prevalence)
1985–1987 1991 1991–93 1989–91 1991–1993 1995–1997
Number of subjects eligible 1440 in 1992 2,835 601 16,261 6,028 4,678 5,677
Years for re-examination yearly 1988–90
1991–92
1994–95
1998–99
2002–2003
1994
1996
1999
1992
1995
1998
2000
2002
1991–93
1997–98
1999
2002
1994–1996
1997–1999
2000–2001
2002–2003
2004- in progress
1998–2000
2004- in progress
Number of subjects 
followed initially (% of 
those eligible)
1436 (99.7%) in 1992 2609 (92%) 553 (92%) 13009 (80%) 5222 (87%) 3734 (79.8%) 5092 (89.7%)
Age at start of study, mean 
(range) in years
Men 73 (65–92)
Women 74 (65–98)
81 (75–106) 89 (85–90+) 75 (65–105)^ 79 (65–108) 78 (71–93) 74 (65–90+)
% men at start of study 40 34 21 40 47 100 42
Number of brains collected 176 (1985–1992) + 
105 (1998–2001)
225 (as of mid 2004) 305 (as of 2002) 370 103 (as of mid 2004) 559 (as of 2004) 65 (+5 whom have not 
completed clinical 
assessment) (as of 2002)
* different interviewing strategy than the other 5 centres
^ stratified to have equal numbers above and below 75B
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Table 2: Clinical and neuropathological standards and tests followed by the selected studies
Studies Hisayama 
Study
CC75C Vantaa 85+ CFAS HAAS Cache County 
study
Dementia clinical diagnosis 
criteria
Screening tools and general 
measures for cognitive decline
MMSE X X X X X
3MS X
IQCODE X X
HAS *
SPMSQ X
MHIS X X
Cummings-Benson X
Blessed dementia scale * X
Neuropsych. Inventory X
Dementia Questionnaire * X
CASI
CAMDEX * X
AGECAT X
CAMCOG * X X
GMS X
CDR X X X X
DSR X
DSM-III-R X * X X X X
Dementia type diagnosis 
criteria
NINCDS-ADRDA X X X X
IWG-NINCDS-AIREN X X
ADDTC X
Hasegawa's Dementia Scale X
Neuropat hological investigation standards NIA-RI X
CERAD X X X X X X
Blood sample collected * in some X * in some X XB
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Neuroimaging X in some * postmortem 
MRI on 145 
brains
XX
Depression diagnosis criteria Hamilton Depression Scale X
Clinical Interview for Depression X
Nottingham Life Satisfaction Index X
Zung Depression Status Inventory X X
Activities of Daily Living ADL X X X X
IADLS * X *
Modified Townsend ALD Scale X
Other Neurologic 
examination 
Hearing and vision 
tests
Videos East Boston 
Memory Tests
X Data routinely collected with some mention in published literature
* Data known to have been collected although not referred to yet in the literature
3MS – modified Mine Mental State Examination [116]
ADDTC – California Alzheimer Disease Diagnostic and Treatment Centers (used for clinical diagnosis of Vascular Dementia) [117]
ADL – Activities of Daily Living [118]
AGECAT – Automated Geriatric Examination for Computer-Assisted Taxonomy [119]
CAMCOG – Cambridge Cognition Examination [120]
CAMDEX – Cambridge Examination for Mental Disorders of the Elderly [121]
CASI – Cognitive Abilities Screening Instrument [122]
CDR – Clinical Dementia Rating [123]
DSR – Dementia Severity Rating Scale [124]
GSM – Geriatric Mental State [125]
HAS – History and Aetiology Schedule (informant interview) [109]
IADLS – Instrumental Activities of Daily Living Scale [126]
IQCODE – Informant Questionnaire on Cognitive Decline in the Elderly [127]
IWG-NINCDS-AIREN – International Work Group of the National Institute of Neurological and Communicative Disorders and Stroke and the Association Internationale pour la Recherche et 
l'Enseignement en Neuroscience (used for the clinical diagnosis of Vascular Dementia) [128]
MMSE – Mini Mental State Examination [129]
MHIS – Modified Hatchinski Ischaemic Score [130, 131]
NINCDS-ADRDA – National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association [132]
SPMSQ – Short Portable Mental Status Questionaire [133]
Table 2: Clinical and neuropathological standards and tests followed by the selected studies (Continued)BMC Neurology 2006, 6:2 http://www.biomedcentral.com/1471-2377/6/2
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briefly described by date of recruitment of baseline popu-
lation. Reference lists for each study are not exhaustive.
The Hisayama study is a prospective cohort study, which
has been carried out since 1961 in a Japanese subrural
community in Hisayama, Japan. The initial aim was to
explore the epidemiology of cerebrovascular diseases.
Starting in 1985, the prevalence of dementia was investi-
gated among residents aged 65 and over. The study
recruited a series of three cohorts (in 1985, 1992 and
1999) and in 1992 it had a huge response rate at baseline
with 99.7% (= 1436) of the eligible population enrolled.
Between 1985 and 1992, 82% (= 176) of the participants
who died underwent brain examination at autopsy;
between 1998 and 2001, the autopsy rate was 70.5% [15-
19].
The Cambridge City over 75 Cohort Study (CC75C) is a
long-term British follow-up study of a population sample
of around 2,600 people aged 75 and above, also begun in
1985 [143]. The study started as the Hughes Hall Project
for Later life (dementia prevalence phase) then became
the Cambridge Project for Later Life (first incidence
phase), before being renamed CC75C. The original study
targeted all people who were registered with selected
group general practices in Cambridge (sampling based on
availability of universal health care free at the point of
delivery in the UK), including those in institutions, and
achieved a 92% response rate at baseline [20-26].
The Vantaa 85+ Study is based on an unselected prospec-
tive population-based sample of all individuals aged 85 or
over living in the city of Vantaa, in Southern Finland, on
April 1, 1991. There was a 92% response rate with 553
subjects taking part in the study. The Vantaa 85+ has the
second highest proportion of autopsies of all the selected
studies with 55% of the initial population having donated
their brain by 2002 [27-33].
The Medical Research Council Cognitive Function and
Ageing Study (CFAS) is based on six centres in England
and Wales (Cambridgeshire, Gwynedd, Newcastle upon
Tyne, Nottingham, Oxford and Liverpool). The study
population was a random sample from registers of general
practices, of around 2,500 people for the first five centres
and 5,222 people in Liverpool. The response rates were
82% for the five first centres, and 87% in Liverpool so that
there were 18,131 respondents at baseline. The only selec-
tion criterion for initial screening was age, respondents
being 65 years old and over at baseline (1991–93) [34-
44].
The Honolulu-Asia Aging Study's (HAAS) source popula-
tion are survivors recruited in 1991 from the cohort of the
Japanese-American men who were examined as part of the
Honolulu Heart Program from 1965 to 1971 and re-
examined in late age. The original cohort of 8,006
respondents included all men born between 1900 and
1919 and living on the island of Oahu and represented
65% of the target population. At the 1991 baseline there
was a 79.8% response rate with 3,734 subjects taking part
in the study of cognition (30% of the original cohort con-
tacted in 1965). One of the major objectives of HAAS was
to compare rates of dementia in a cohort of Japanese-
American men in Hawaii with rates of Japanese living in
Japan and the United States mainland [45-63].
The Cache County Study of Aging and Memory's (Cache
County study) source population are residents (including
those living in institutions) of Cache County, Utah (USA),
who were aged 65 years or older on January 1, 1995. This
population has an exceptional longevity, especially for
men whose conditional life expectancy at age 65 is the
highest in the United States and exceeds national averages
by almost 10 years. There was an 89.7% response rate with
5,092 subjects taking part in the study at baseline [64-79].
Core information for these six studies can be found in
(Table 1). Clinical and neuropathological standards and
tests used by the studies are in (Table 2).
Examples of excluded studies
Additional File 1 shows examples of studies identified
during the search but which did not meet the inclusion
criterion in that respondents recruited to the neuropatho-
logical component should include all subgroups of the
relevant local population. All the non-selected studies
were based on people referred to various clinics, people
living only in institutions or only in the community, peo-
ple signed up on a non-universal health care system or
volunteers. The geographical boundary was not a criterion
that excluded studies in itself but chosen because it offers
the clearest way of avoiding selection bias which may be
related to dementia status. While many excellent popula-
tion-based cohorts exist (PAQUID, ILSA, The Rotterdam
Elderly Study, etc), few have collected neuropathological
data [3-5,80-89].
Hypotheses tested in the six existing population-based 
neuropathological studies
Additional File 2 shows the scope of investigations pre-
sented in publications from the six retained studies. A
summary of the findings for a selected number of papers
is included.
The key areas from these studies include:
(1) Clinicopathological correlation and use of postmor-
tem-confirmed diagnosis (most frequent type of pub-
lished work);BMC Neurology 2006, 6:2 http://www.biomedcentral.com/1471-2377/6/2
Page 8 of 16
(page number not for citation purposes)
(2) Assessing standards and staging models;
(3) Association between neuropathologies and risk fac-
tors;
(4) Genetic investigation in relation to autopsy-confirmed
diagnosis or specific neuropathologies.
Discussion
Characteristics of the cohorts
All six studies chose their source populations according to
geographical area and age. The Hisayama study, CFAS and
the Cache County study selected for a population aged
over 65, while HAAS selected for over 72, and CC75C for
over 75. The Vantaa 85+ study included all individuals
aged 85 and over thus representing the very elderly. Inter-
pretation of findings must take these design strategies into
account. For example, in a study of people surviving to
85+ years differential survival rates may affect genetic
findings such as true homozygous for Apoe E4 individuals
because they are at increased risk for premature death
from cardiovascular disease and similar causes, and there-
fore likely to be underrepresented in populations of older
individuals [90]. Studying a very elderly population may
introduce new sources of bias but also provide new
insights.
By definition all six studies sought community-dwelling
and institutionalised respondents. This requirement to
include institutionalised persons in a representative com-
munity sample in dementia studies has been challenged.
Based on a meta-analysis covering prevalence studies
from 1945 to 1985, Jorm and colleagues found no effect
on the overall prevalence rates of dementia [91]. They
argued that institutionalised individuals represent only a
small proportion of the elderly population and thus
effects are marginal. However, there are secular changes in
institutional rates and variations across countries and cul-
tures [92]. In a German study of people over 75
(LEILA75+) it was found that institutionalised individuals
were seven times more likely to be demented than com-
munity-dwelling individuals, but they were also older,
more often single and less often married [93]. In the CFAS
population, 62% of those living in institutions were
demented and represented 34% of those with dementia in
the whole study cohort [94].
Each study population has characteristics which influence
how generalisable the findings are, but which may also
relate to the rationale behind selecting the study area. The
Cache County study sample was chosen because it was
not typical of the present USA population as a whole. A
great majority of the respondents did not smoke or drink
alcohol and 91% were members of the Church of Jesus
Christ of Latter-Day Saints – factors which may contribute
to the average longevity among men in the study that
exceeds the USA national average by almost 10 years.
HAAS is also restrictive in the sense that it only includes
men, who do not represent the majority of dementia suf-
ferers in the population. It was created out of several
cohorts with a different initial purpose, which was the
investigation of the effect of migration on vascular risk. It
could be argued that these two studies are more akin to
the selected cohort studies than to the true population-
based studies in that there may be limited generalisability
from their findings. CFAS is the only multicentre study
mixing populations from both rural and urban settings
but has little ethnic variation.
To date these studies have not presented their findings
with any attempt to weight back to the population. For
now, study size, initial response rate, and attrition are
important factors that determine whether a study using an
autopsy endpoint is truly population-based. Large study
populations are needed for adequate statistical power to
detect relationships between variables, such as the effect
of specific gene polymorphisms. Initial response rates and
follow-up rates need to be high, and maintained, to retain
the representativeness of the group. All six studies showed
high initial response rates. These range from 79.8%
(HAAS, sampled from the 65% follow-up cohort studied
from 1965–1971), to 92% (Vantaa 85+ and CC75C) and
a remarkable 99.7% for the Hisayama study in the 1992-
screening wave. Attrition varied across the studies. Due to
the greater age of the baseline Vantaa 85+ respondents
had a higher death rate between each follow-up compared
to the other studies. Approximately one-half of the sub-
jects had died by the 3-year follow-up but 97.3% of survi-
vors were re-examined [95]. In CC75C, the two-year
incidence wave achieved 67% follow-up of all respond-
ents, and an 81% follow-up of all survivors [23]. Similar
reporting of attrition is made in CFAS, HAAS and the
Cache County study publications.
The problem of non-response can be especially important
for the population study of cognitive status in the elderly
because cognitive compromise is a predictor of non-
response. Non-response in the Cache County study was
related to lower levels of cognitive functioning, as meas-
ured by the MMSE, than initial responders [74]. They also
reported that the sample under-represented females,
younger individuals and people from other ethnic or reli-
gious backgrounds than members of the Church of Jesus
Christ of Latter-Day Saints. The CC75C study also
reported a lower baseline MMSE score (-1.17) in those
who did not participate at follow-up, although 15% of
these non-responders were initially interviewed but did
not complete the assessment [36]. It is likely that these
MMSE scores were disproportionately low at the interview
and so the effect of MMSE on not being interviewed at allBMC Neurology 2006, 6:2 http://www.biomedcentral.com/1471-2377/6/2
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will not be as high as -1.17 [96]. In CFAS, looking at lon-
gitudinal attrition, predictors for drop out due to death
were being older, male, having impaired activities of daily
living, poor self-perceived health, poor cognitive ability
and smoking. Similarly individuals who refused were
more likely to have poor cognitive ability but had less
years in full-time education and were more often living in
their own home though less likely to be living alone [97].
Further investigation into the characteristics of those lost
to follow-up after initial enrolment was not reported by
the other selected studies. This also includes investigating
those lost to follow-up because of death. The Vantaa 85+
study and CFAS report that death certificates were checked
to identify new dementia cases among those who were
not demented in the last interview. This strategy is under-
mined because the recording of dementia on death certif-
icates is notoriously unreliable [98-100]. Other
longitudinal studies of ageing and dementia have also
suggested that mental status scores predict attrition [101]
so that the influence of non-responders on the findings
should not be minimised. In spite of this, none of the six
studies could be excluded according to this criterion.
These are all large population studies dealing with the
older population where in any case high attrition is
expected and where ethical approval usually does not
allow approach of those who decline future participation.
How representative were the autopsy samples compared 
to all deaths in the initial cohorts?
In volunteer cohorts such as the Nun Study, very high
rates of autopsy amongst the deaths are achieved. How do
population-based studies compare? The six studies vary in
the proportion of brains collected in relation to their sam-
ple populations. The Hisayama study and Vantaa 85+
have autopsied between 70% and 82% (depending on
years) and 52% of respondents respectively. These are
remarkable autopsy rates in the context of a global decline
in autopsies [102]. HAAS' autopsies were discussed with
all examined participants at the 1991–93 and 1994–96
examinations and the study has collected 559 brains so far
(equal to 15% of the number of participants at the 1991
baseline). CFAS has performed 470 autopsies and another
250 are pledged. This is equal to around 40% of those
approached to take part in the donation programme. Fac-
tors such as whole body donation, non-notification of
death, coordination difficulties or changes of decisions at
or before death, all result in erosion of the 'population
representativeness' of the autopsy cohort. The possibility
that systematic biases relate to the willingness of respond-
ents to countenance brain donation has not often been
studied. In one study of healthy elderly people, agreement
to brain donation was related only to age and the Cornell
Depression Scale score. Older respondents (≥ 85 years of
age) were more likely to consent to donation than
younger ones [103]. Another study investigating the dif-
ferences in pre-morbid clinical diagnoses between autop-
sied and non-autopsied dementia patients, the autopsied
individuals differed in age, race, and interval between the
last clinical contact and death compared to those who did
not [104]. Those patients with early onset of disease (<65)
were more likely to consent to autopsy than those whose
illness began somewhat later in life. A key motivating fac-
tor for agreeing to post-mortem examination is personal
knowledge of an AD patient [105]. These findings are
reassuring and suggest that even though autopsies are vol-
untary, they do not seem to be skewed to one segment of
the demented population.
HAAS, Vantaa 85+, CFAS and CC75C have all addressed
the representativeness of their autopsy group. In HAAS the
autopsy sample was similar to the total cohort in terms of
sociodemographic terms, cognitive status and late life
cholesterol levels. The autopsy rate was approximately
50% among the participants who had been recognised as
demented with the autopsy rates being similar for the four
clinically diagnosed subtypes of dementia [45,61]. Vantaa
85+ reported slight differences in the age and sex between
the autopsied and the non-autopsied subpopulations
[27]. CFAS and CC75C used sampling strategies that
enriched the autopsy sample to include older and more
impaired respondents but other than these characteristics
there was no clear indication that the donor sample dif-
fered from the general population in basic sociodemo-
graphic indicators [20,34].
Even though brain donations may not be biased regarding
dementia status, other factors could introduce error into
the autopsy process such as lack of notification of the
study team because of the place of death: hospital, institu-
tion or home. The rapid accessibility to the body and the
idea that it is likely that cognitive decline has a difference
course in patients who are institutionalised compared to
those who remain at home until the end of their life both
play a part in the generalisability of the findings. One
must assess the impact of only including a small propor-
tion of individuals who die at home in an autopsy study
[106]. HAAS clearly reported the place of death of its
cohort members whom have undergone autopsy, this
being 71% in the hospital. 13.1% at home, 11.2% in a
nursing home and 4.6% in a hospice or other place [61]
although none of the studies have reported on 'missed'
autopsies.
Case identification, examination and in life diagnosis
Even if the initial cohort is population-based, studies may
lose their population representation because of their case
identification strategy. This arises if they rely on studying
cases that have already come in contact with the health
care system. For example, one of the excluded studies, the
University of Washington Alzheimer's Disease PatientBMC Neurology 2006, 6:2 http://www.biomedcentral.com/1471-2377/6/2
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Registry (ADPR), uses a base population comprising
members of a Group Health Cooperative with an attrition
rate less than 1% per year. However, cases are found
through the primary care physician network, referral from
neurologists and mental health services or by monitoring
events leading to the entry of demented patients into the
health-care system [107]. Dementia cases remaining in
the community are therefore under-represented. There is
no organised population-based or primary-care effort
directed at the early detection of dementia in the USA and
in the UK primary care physicians have reported that
fewer than 50% have adequate basic and post-qualifying
training for identifying dementia [108]. One can fairly
assume that many dementia cases go unnoticed in the
health care system and that such a design results in a sam-
ple with limited population representation.
All the studies reported here have used direct interviewing
of the populations identified with standardised assess-
ments (Table 2). Clinical assignment of a dementia diag-
nosis was undertaken in three of the studies by consensus
between expert clinicians. The Cache County study set up
diagnostic conferences including geropsychiatric, neurol-
ogy, neuropsychology and cognitive neuroscience exper-
tise and the final diagnosis was achieved using
information from all phases of the study including the
autopsy results. HAAS and Vantaa 85+ achieved clinical
diagnosis through smaller clinician panels and CC75C
used a single psychiatrist with inter-rater reliability tests.
CFAS based its findings on a previously validated clini-
cally based computer-assisted taxonomy (AGECAT)
administered by trained lay research interviewers [109].
Neuropathological case confirmation
The comprehensiveness and comparability of the neu-
ropathological investigation varies more in population
settings. All more or less closely followed the Consortium
to Establish a Registry for Alzheimer's Disease (CERAD)
neuropathology protocol [13]. This is in contrast to the
broader variation in methods for clinical diagnosis (Table
2). Details of neuropathological investigations are yet not
available in the published literature for the Cache County
Study. In Vantaa 85+, besides completing the CERAD pro-
tocol, the NIA-RIA criteria was also adopted which
emphasises topographic staging of neurofibrillary
changes in addition to neuritic plaques [110,111], and the
investigators routinely sampled additional areas of the
brain supplementing the usual techniques with immuno-
cytochemical methods to enhance detection of amyloid
and Lewy bodies. Regarding how many neuropathologists
carried out the examination: in CFAS, the Hisayama study
and HAAS, postmortem investigation was performed by
several neuropathologists, while in the Vantaa 85+ study,
for one study looking at brain infarctions, the examina-
tion was done by one pathologist. No information is
given for the Cache County Study. Comparability of
assessment has been checked within CFAS and HAAS.
The CERAD protocol gives guidelines for tissue fixation,
tissue processing, sectioning and tissue staining. It pro-
vides a simple semiquantitative systematic gathering of
information on clinical, neuropsychological and neu-
ropathologic aspects reducing subjective interpretation
[13,112]. Nonetheless, the assignment of probability of a
diagnosis of AD by the CERAD approach is based on con-
cepts of clinicopathological correlation derived from
cohort studies of selected cases and 'controls' so that it
may represent a biased view of what burden of lesions are
associated with a positive diagnosis for dementia. For
instance, CERAD uses abundant neuritic plaques as a ref-
erence for AD case definition, reinforcing the concept of
AD as a disorder of amyloidosis. The relationship between
lesion burden and cognitive status, and the interactions
between lesions, differs in a population sample from
those in selected secondary referral cohorts of demented
people [34]. It is increasingly acknowledged that the pro-
portion of normal elderly individuals with a substantial
neuropathological burden is not negligible [34,106,113].
The logical aim of neuropathological studies of dementia,
if no neuropathological 'gold standard' exists, would be to
collect information in an unbiased way to test which diag-
nostic criteria are most valid and reliable.
The CERAD protocol was developed in the 1980s and is
based on a paradigm which heavily relied on the signifi-
cance of lesions such as neurofibrillary tangles and amy-
loid plaques as the pathological substrate of cognitive
decline. The accumulation of data from many studies over
the last 15 years underline the limitations of this
approach. The CERAD protocol ignores a number of path-
ological and biochemical advances which have identified
additional targets, or refined the basis for quantifying
pathologies, that are likely to have a closer link with cog-
nitive decline or are additional pathologies that are not
taken into account. These newer approaches include: bio-
chemical estimations of soluble amyloid peptide load and
aberrant tau accumulation in brain regions, synaptic den-
sity measurements, glial responses such as astrogliosis and
microgliosis, severity of white matter attenuation. Finally
CERAD provides no basis for assessing the significance of
microvascular pathologies in the causation of cognitive
decline.
A significant limitation is imposed through the necessity
to adopt a validated pathology protocol with documented
inter-laboratory comparability. In CERAD, 83% of raters
showed consistency for plaque determination, whereas
only 66% showed consistency for tangle determination.
Despite this, apart from bias resulting from knowledge of
dementia status before death, most of the other types ofBMC Neurology 2006, 6:2 http://www.biomedcentral.com/1471-2377/6/2
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variation should produce non-systematic bias and there-
fore underestimate any relationship [11]. Mirra has
remarked that 'whether this variation is produced by dif-
ferences in the phase of the moon or other indeterminate
factors remains unclear, but, in my view, standardisation
of methodology will be difficult to achieve' [114]. The six
studies report few measures taken to assure or measure
quality in the neuropathological investigation. Blinding
of the neuropathologist to clinical and risk factor data is
reported for Vantaa 85+, CC75C and CFAS. Neuropatho-
logical inter-rater reliability was only described by CFAS.
Timing of data collection
Each study up-dated their data in life around every 2 years.
In population studies it has been accepted that it is not
feasible to have regular clinical follow-up until death for
each member of a large study cohort despite the desirabil-
ity of minimising the time interval between the last exam-
ination and death [106]. This interval is critical in
determining whether pathological features at autopsy are
a reflection of the cognitive state at last interview. Health
checks were done at least once a year in the Hisayama
study. For Vantaa 85+ the average length of time from the
last clinical examination to death was 0.99 y (range 0.05
– 2.35 y), for HAAS, the average was 2.4 y (SD 0.9 y) and
for CFAS 1.2y (range of 3 d – 4.2 y; 81% within 2 y). In
CC75C the study design and timing of the interview waves
suggests the interval between last clinical examination
and death is usually less than 3 years unless follow up
interview was refused. Details have not been published
yet for the Cache County study. Using various informant
interviews may help in gaining a truer cognitive picture of
the participant if delays between follow-up and death are
considered too long. Studies which report the use of
informant interviews can be found in (Table 2).
The timing of autopsy and methods of handling after
death are also important for molecular studies. Formalin
fixing plays a role in any future neuropathological exami-
nation and affects the sensitivity of the immunocyto-
chemistry results. This variable depends on the work force
available to complete the neuropathological examina-
tions at the time of death and is thus dependent on the
level of funding for the study and the relative importance
given to such studies in their research and cultural con-
texts. None of the studies have reported time between
death and autopsy although this is usually available in
mortuary records.
Comparing and combining studies
Research based on community samples has the advantage
that it allows the calculation of attributable risk, popula-
tion attributable risk and population excess risk, which
can all estimate how important a given factor is in a par-
ticular population. Each study has used similar neu-
ropathological standards but this does not necessarily
imply that the results are directly comparable. This is illus-
trated by the example of the classification of 'possible' and
'probable' cases of dementia. HAAS has described mutu-
ally exclusive subcategories of dementias: AD as primary
cause, Vascular Dementia (VaD) as primary cause, mixed
AD/VaD and other types of dementias [63] rather than
risking misclassification of mixed cases; whereas in the
Vantaa 85+ study, no 'mixed dementia' category is men-
tioned [27]. Combining of clinical information should be
possible if one goes back to specific measures within each
study. Unfortunately there is little overlap in the areas
investigated amongst the six existing population-based
neuropathological studies so that a systematic review of
their results is not possible.
Redefining the field
Despite all the effort put into setting up the studies and
gathering evidence, these datasets remain as yet under-
tapped resources. So far most population-based studies
have used post-mortem information to test or validate
clinical diagnoses. Few have taken the opportunity to
challenge and re-characterise existing criteria. Until rela-
tively recently clinicopathological studies have concen-
trated on clinically clear-cut cases of AD but these
population-based studies have confirmed that there is
considerable overlap in pathologies found in the
demented and non-demented [20,34,45]. For example in
HAAS, 33% of demented subjects' condition could not be
attributed to any of four primary pathogenic processes or
to a combination of them (vascular lesions, AD lesion pat-
terns, hippocampal sclerosis and cortical Lewy bodies).
The same heterogeneity of lesions was found in CC75C.
In CFAS' first 209 autopsies, both cerebrovascular (78%)
and Alzheimer type (70%) pathology were common.
Dementia was present in 48% of whom 64% had features
indicating probable or definite AD. 33% of the non-
demented people, however, had equivalent densities of
neocortical neuritic plaques. Some degree of neocortical
neurofibrillary pathology was found in 61% of demented
and 34% of non-demented individuals. Vascular lesions
were equally common in both groups, although the pro-
portion with multiple vascular pathology was higher in
the demented group (46% vs. 33%). In the same way,
Vantaa 85+ findings show that the prevalence of neu-
ropathologically defined AD was 33% whereas the preva-
lence of clinically diagnosed AD was 16%. Although there
was a correlation between clinical AD and neuropatholog-
ical AD, 55% of individuals with neuropathologic AD
were either in the non-demented group or in the Vascular
dementia (VaD) or other clinical non-AD groups. On the
other hand, 35% of those with clinical AD did not fulfil
the neuropathologic criteria for AD used in the study. The
Cache County study reported 21% of mixed dementiaBMC Neurology 2006, 6:2 http://www.biomedcentral.com/1471-2377/6/2
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diagnosis using a consensus between clinical and autopsy
findings.
Conclusion
The aim of this paper was to carry out a systematic review
of all existing population-based neuropathological stud-
ies of old age dementia to assess the representativeness of
their study populations and to review their neuropatho-
logical investigation methods. The review considers study
design and the range of investigations undertaken. Refer-
ral and volunteer cohort studies tend to hold more com-
plete and extensive information and have fewer problems
in terms of attrition. Population-based studies on the
other hand demand prodigious organisation and effort
over a prolonged period and result in a potentially rich
source of data to help understand the aetiology and
pathogenesis of late life dementia with less bias. The six
studies together with their 1,200+ brains directly relate to
a base population of near 32,000 people. New work could
be indicative such as testing genetic polymorphisms. They
have the ability to take the valuable findings from clinical
series and volunteer cohorts and estimate how important
findings are for the community as they have the only set-
ting which permit an unbiased extrapolation of the results
to the general population. With their abundance of
recorded clinical and neuropsychological information,
these studies could help in the constructive challenge to
existing neuropathological criteria and create new
hypotheses about the biological substrates of cognitive,
functional and behavioural changes with age. These stud-
ies are rare globally and can provide unique insights. Indi-
vidually they are limited in power and scope; together
they represent a powerful resource to translate findings
from laboratory to populations.
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